LANNA SMITH: Open Payments
NPI 1366515561 · ARLINGTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$611 in 27 payments from 11 companies in 2025. Trend: 2023 $251 · 2024 $334 · 2025 $611
Food & beverage: $611
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $168 |
| Amgen Inc. | 5 | $95 |
| SCPHARMACEUTICALS INC. | 3 | $83 |
| PFIZER INC. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Lilly USA, LLC | 1 | $32 |
| Merck Sharp & Dohme LLC | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: LEQVIO, REPATHA, FUROSCIX, ELIQUIS, CAMZYOS, ZEPBOUND, VERQUVO, OPSUMIT.
Industry payments across VA — which companies pay providers there.
